Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty
- Registration Number
- NCT00772395
- Lead Sponsor
- Danderyd Hospital
- Brief Summary
Can risedronate given once weekly for 6 months prevent periprosthetic bone loss after uncemented total hip arthroplasty?
- Detailed Description
Periprosthetic bone loss after total hip arthroplasty is the main factor in limiting the longevity of implants used for treatment of osteoarthritis. Bone loss leads to implant destabilization. Bisphosphonates, given for approximately 6 months after THA man prevent this bone loss and lead to longer implant fixation and lower incidence of aseptic prosthesis loosening. We perform a clinical trial with risedronate to investigate if we can influence periprosthetic bone loss around a uncemented femoral stem.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 78
Inclusion Criteria
- Patients on the waiting list for a total hip arthroplasty
- Primary osteoarthritis
- Osteoarthritis secondary to congenital dislocation of the hip
Exclusion Criteria
- Rheumatoid arthritis
- Bisphosphonate treatment
- Osteomalacia
- Hypocalcemia
- Previous surgery of the affected hip
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Risedronate Risedronate - Placebo Placebo -
- Primary Outcome Measures
Name Time Method Can risedronate given once weekly for 6 months prevent periprosthetic bone loss up to 2 years after uncemented total hip arthroplasty 4 years
- Secondary Outcome Measures
Name Time Method Can risedronate reduce migration of a uncemented femoral stem 4 years
Trial Locations
- Locations (1)
Orthopaedic department, Danderyd Hospital
🇸🇪Stockholm, Sweden